跳转至内容
Merck
CN
所有图片(1)

主要文件

528100

Sigma-Aldrich

PI-103

A cell-permeable pyridinylfuranopyrimidine compound that acts as a potent and ATP-competitive inhibitor of DNA-PK, PI3-K, and mTOR.

别名:

PI-103, 3-(4-(4-吗啉基)吡啶并[3ʹ,2ʹ:4,5]呋喃并[3,2-d]嘧啶-2-基)苯酚,mTOR抑制剂V,PI 3-K抑制剂V

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H16N4O3
分子量:
348.36
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥97% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

white

溶解性

DMSO: 5 mg/mL

运输

ambient

储存温度

−20°C

SMILES字符串

N5(CCOCC5)c1nc(nc3c1[o]c4ncccc43)c2cc(ccc2)O

InChI

1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2

InChI key

TUVCWJQQGGETHL-UHFFFAOYSA-N

一般描述

一种可渗透细胞的吡啶基呋喃嘧啶化合物,可作为DNA-PK,PI3-K和mTOR的强效和ATP竞争性抑制剂(DNA-PK,p110α,p110β,p110δ,p110γ,PI3-KC2β,mTORC1和mTORC2的IC50分别为2、8、88、48、150、26、20和83 nM)。 它仅在更高的浓度(分别为IC50=850和920 nM)下抑制ATR和ATM,并且即使在浓度高为10 µM时,对一组40多种其他激酶也几乎没有活性。已证明可有效阻断体外体内胶质瘤细胞系中的PI3-K/Akt信号传导和细胞增殖。也可购买10 mM(2 mg/574 µl)PI-103 DMSO溶液(目录号528101)。

生化/生理作用

主要靶标
DNA-PK,PI3-K和mTOR
产物与ATP竞争。
可逆:否
细胞可渗透性:具有
靶标IC50:DNA-PK,p110α,p110β,p110delta;,p110γ,PI3-KC2β,mTORC1和mTORC2分别为2、8、88、48、150、26、20和83 nM

包装

用惰性气体包装

警告

毒性:标准处理(A)

制备说明

完全溶解可能需要轻微加热。

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Qi-Wen Fan et al.
Cancer cell, 9(5), 341-349 (2006-05-16)
The PI3 kinase family of lipid kinases promotes cell growth and survival by generating the second messenger phosphatidylinositol-3,4,5-trisphosphate. To define targets critical for cancers driven by activation of PI3 kinase, we screened a panel of potent and structurally diverse drug-like
Florence I Raynaud et al.
Cancer research, 67(12), 5840-5850 (2007-06-19)
Extensive evidence implicates activation of the lipid phosphatidylinositide 3-kinase (PI3K) pathway in the genesis and progression of various human cancers. PI3K inhibitors thus have considerable potential as molecular cancer therapeutics. Here, we detail the pharmacologic properties of a prototype of
Zachary A Knight et al.
Cell, 125(4), 733-747 (2006-05-02)
Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined. We describe here an approach to pharmacologically interrogate the PI3-K family. A chemically diverse panel of PI3-K inhibitors was
PtdIns(3,4)P2, Lamellipodin, and VASP coordinate actin dynamics during phagocytosis in macrophages.
Monta??o-Rend??n, et al.
The Journal of cell biology, 221 (2023)
Franz F Dressler et al.
Nature communications, 15(1), 4513-4513 (2024-05-28)
Urothelial bladder cancer (UC) has a wide tumor biological spectrum with challenging prognostic stratification and relevant therapy-associated morbidity. Most molecular classifications relate only indirectly to the therapeutically relevant protein level. We improve the pre-analytics of clinical samples for proteome analyses

商品

AldeRed™ 588-A detects ALDH activity in cancer stem cells, aiding in cancer research.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门